Initial Experience Prescribing Commercial Tafamidis, the Most Expensive Cardiac Medication in History
Open Access
- 1 September 2020
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 5 (9), 1066-1067
- https://doi.org/10.1001/jamacardio.2020.1738
Abstract
This economic evaluation study examines the authors' experience of prescribing tafamidis in terms of their cost and the insurance status of patients.This publication has 3 references indexed in Scilit:
- Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid CardiomyopathyCirculation, 2020
- Tafamidis-A Pricey Therapy for a Not-So-Rare ConditionJAMA Cardiology, 2020
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyThe New England Journal of Medicine, 2018